FerroptoCure Selected for the AMED “Strengthening Program for Pharmaceutical Startup Ecosystem” ― Eligible for up to JPY 10 billion (~USD 65 million) in the Grant

FerroptoCure Inc. (Headquarters: Tokyo, Japan; CEO: Yuji Otsuki) is pleased to announce that it has been selected for the “Strengthening Program for Pharmaceutical Startup Ecosystem” funded by the Japan Agency for Medical Research and Development (AMED). Through this program, FerroptoCure will be eligible for up to JPY 10 billion (~USD 65 million) in the grant.

This program is designed to strengthen the foundation for pharmaceutical startups in Japan and accelerate the creation of innovative medicines. FerroptoCure is developing the world’s first ferroptosis-inducing small-molecule anticancer drug, and with this support, we will further accelerate the realization of novel therapies for a wide range of cancers, including refractory and treatment-resistant cancers. In addition, we plan to conduct clinical trials overseas and pursue international expansion in both R&D and business operations, strengthening our presence and collaborations globally.

As a Keio University School of Medicine spin-off biotech venture, FerroptoCure is committed to delivering new treatment options to patients through innovative drug discovery targeting ferroptosis, a novel form of regulated cell death. We will continue to strengthen collaborations with domestic and global research institutions and pharmaceutical companies to advance the development of next-generation cancer therapies.

👉 More details on the AMED website:
・About the Strengthening Program for Pharmaceutical Startup Ecosystem: https://www.amed.go.jp/program/list/19/02/005.html
・About FerroptoCure's Selection for the FY2025 “Strengthening Program for Pharmaceutical Startup Ecosystem ((8th Call)”:
https://www.amed.go.jp/koubo/19/02/1902C_00063.html